Seegene's Allplex™ SARS CoV-2 FluA/FluB/RSV Assay Approved Under Health Canada's Interim Order
Complete the form below to unlock access to ALL audio articles.
Seegene Inc., South Korea's leading molecular diagnostic company, announced it has received approval of its Allplex™ SARS CoV-2 FluA/FluB/RSV Assay under Health Canada's Interim Order on January 11.
Seegene's Allplex™ SARS CoV-2 FluA/FluB/RSV Assay is a multiplex real-time PCR assay that enables simultaneous amplification and differentiation of respiratory symptoms. In a single test, it can distinguish among Influenza A, B, RSV, and COVID-19. This assay expected to play a crucial role in responding to the potential 'twindemic' as the country is forecasting a surge in both flu patients and COVID-19 patients.
To support Canada’s surging demand for COVID-19 tests, Seegene delivered 340,000 COVID-19 tests by a charter flight on January 13.
"Demand for COVID-19 tests is skyrocketing due to the resurgence of confirmed cases," said Ho Yi, Chief Sales and Marketing Officer of Seegene. "We are fully prepared to supply enough test kits globally and will continue to be strong partners in the effort to manage the spread of this pandemic."
This latest approval is expected to be a significant opportunity for the company, as it will allow Seegene to raise its product awareness in surrounding countries of Canada such as Latin America and others.
